Insmed reported $-130773000 in Pre-Tax Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acelrx Pharmaceuticals ACRX:US USD -6739000 1.75M
Alimera Sciences ALIM:US USD -5245000 2.15M
Biomarin Pharmaceutical BMRN:US USD -1904000 36.75M
Cytokinetics CYTK:US USD -142310000 122.49M
Heron Therapeutics HRTX:US USD -41882000 14.48M
Insmed INSM:US USD -130773000 35.63M
Mirati Therapeutics MRTX:US USD -173307000 3.14M
Ophthotech OPHT:US USD -42351000 6.91M
Regeneron Pharmaceuticals REGN:US USD 1.45B 140.6M
Sarepta Therapeutics SRPT:US USD -256418000 28.32M
Seattle Genetics SGEN:US USD -188527000 53.81M
Ultragenyx Pharmaceutical RARE:US USD -238819000 80.96M